Dr. Axe Wire · Food, herbs & supplements · gut

Fiber-Gut Bacteria Pathway Aids Healing in Mice, Not in Colitis Trial

A dietary fiber helped mice recover from colitis through gut bacteria and an amino acid, but failed its main goal in people.

By Dr. Josh Axe · November 1, 2026 · 1 source · Watch

Photo: Pexels

At a glance

What they found: Alginate improved colitis recovery in mice.
Who was studied: Mice with chemically induced colitis.

A dietary fiber called alginate helped mice recover from colitis by working through gut bacteria and an amino acid called taurine, but a companion trial in people with ulcerative colitis did not hit its main goal, researchers reported in Microbiota–Taurine Pathway Links Dietary Fiber to Mucosal Healing, published October 21, 2026 in Gastroenterology. In the human arm, patients with ulcerative colitis received a fecal microbiota transplant primed with antibiotics, then were randomly assigned to alginate or a placebo.

Researchers screened fibers in mice with chemically induced colitis and found alginate improved recovery, calming inflammation, restoring the gut lining's barrier and boosting the proliferation of repair cells in the crypts, pouches lining the colon wall. Alginate enriched bacteria that release taurine, including Bacteroides acidifaciens and Ligilactobacillus murinus, and raised intestinal taurine levels; disrupting the gut microbes with antibiotics erased the benefit. Mice genetically unable to transport taurine, or lacking a gene called Cyp2c55, lost the protective effect, showing both were required. In the companion trial, the primary endpoint, the main measure of clinical improvement, was not met.

The authors state that alginate engages a chain of events: fiber feeds specific gut bacteria, those bacteria release taurine, and taurine switches on an epithelial repair gene in mice. Despite missing the main clinical goal, alginate was still linked to changes in fecal taurine levels and in a related colon gene called CYP2C18 in the human patients, which the authors say is consistent with the mechanism seen in mice. Fiber in general feeds the microbes already in your gut, and what they produce can influence the gut lining.

The clinical trial did not meet its primary endpoint; however, the biological changes warrant further investigation of alginate as a microbiota-targeted intervention.

Study authorsGastroenterology, 2026

The human trial did not meet its primary endpoint, even though the underlying biology moved in the expected direction. Sample size, age, sex split and effect sizes for the human trial were not reported in the abstract reviewed. The mechanism comes from mice and lab-grown organoids; a trial sized to detect a real clinical benefit is the next step.

Dr. Axe’s Take

If you have ulcerative colitis, this is not a fix yet: the human trial missed its primary goal. What I find useful is the mechanism: fiber feeding gut bacteria that release taurine, which then switches on a gut-repair gene in mice. That is one more reason to eat fiber-rich foods like oats, beans, lentils and vegetables, since gut bacteria depend on them to make protective compounds in the first place. For anyone managing ulcerative colitis, keep working with a gastroenterologist on the prescribed treatment plan and treat fiber as a diet-quality habit, not a replacement therapy.

— Dr. Axe

Take the Gut Health Quiz →

Story summary

Who: Mice with chemically induced colitis; ulcerative colitis patients given a fecal microbiota transplant, then alginate or placebo. Human sample size not reported.
Design: Mouse colitis experiments plus a randomized, placebo-controlled human trial.
Dose: Dietary fiber (alginate) given after an antibiotic-primed fecal microbiota transplant in the human trial; dose not specified in the abstract.
Primary result: Alginate improved colitis recovery in mice; the human trial's primary clinical endpoint was not met.
Secondary: Alginate raised intestinal taurine and switched on a gut repair gene (Cyp2c55) in mice; in patients, fecal taurine and colonic CYP2C18 expression still shifted with alginate.
Funding / conflicts: Funders listed in the journal record: Japan Agency for Medical Research and Development; Japan Society for the Promotion of Science; Japan Science and Technology Agency Strategic Basic Research Programs. Conflicts not reported in the abstract.
Date: Oct 21, 2026